Omada Health, Inc. (OMDA)
| Market Cap | 957.12M |
| Revenue (ttm) | 283.30M +49.4% |
| Net Income | -6.30M |
| EPS | -0.13 |
| Shares Out | 59.45M |
| PE Ratio | n/a |
| Forward PE | 49.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,273 |
| Open | 16.45 |
| Previous Close | 16.52 |
| Day's Range | 15.97 - 16.59 |
| 52-Week Range | 10.28 - 28.40 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 23.00 (+42.86%) |
| Earnings Date | May 7, 2026 |
About OMDA
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for emplo... [Read more]
Financial Performance
In 2025, Omada Health's revenue was $260.21 million, an increase of 53.24% compared to the previous year's $169.80 million. Losses were -$12.78 million, -72.89% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for OMDA stock is "Buy." The 12-month stock price target is $23.0, which is an increase of 42.86% from the latest price.
News
3 Small-Cap Stocks with ‘Strong Buy’ Ratings and Big Upside in 2026
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Napco Security Technologies ($NSSC), MP Materials ($MP), and Omada Health, Inc. ($OMDA) a...
Omada Health Q1 Earnings Call Highlights
Omada Health NASDAQ: OMDA reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adj...
Omada Health price target raised to $20 from $15 at Evercore ISI
Evercore ISI raised the firm’s price target on Omada Health (OMDA) to $20 from $15 and keeps an Outperform rating on the shares.
Omada Health price target raised to $26 from $23 at Goldman Sachs
Goldman Sachs analyst David Roman raised the firm’s price target on Omada Health (OMDA) to $26 from $23 and keeps a Buy rating on the shares.
Omada Health price target raised to $24 from $22 at Canaccord
Canaccord raised the firm’s price target on Omada Health (OMDA) to $24 from $22 and keeps a Buy rating on the shares. The firm said Omada posted a “milestone” quarter…
Omada Health price target raised to $18 from $17 at Wells Fargo
Wells Fargo raised the firm’s price target on Omada Health (OMDA) to $18 from $17 and keeps an Equal Weight rating on the shares. The firm cites a beat &…
Omada Health price target raised to $21 from $18 at Citizens
Citizens raised the firm’s price target on Omada Health (OMDA) to $21 from $18 and keeps an Outperform rating on the shares. Management highlighted potential for gross margins to exceed…
Omada Health reports Q1 EPS (5c), consensus (4c)
Reports Q1 revenue $78.05M, consensus $74.09M. “Surpassing one million Total Members is a milestone that reflects the durable growth and operating leverage we’ve built over 15 years of earning trust…
Omada Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 42% revenue growth, positive adjusted EBITDA, and over 1 million members, driven by strong GLP-1 and cardiometabolic program adoption, expanded PBM partnerships, and AI-powered operational gains. Full-year guidance was raised for both revenue and EBITDA.
Omada Health Earnings release: Q1 2026
Omada Health released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Omada Health Slides: Q1 2026
Omada Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Omada Health Quarterly report: Q1 2026
Omada Health has published its Q1 2026 quarterly earnings report on May 7, 2026.
Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support
SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA) announced it will serve as an independent program administrator in Eli Lilly and Company's Employer Connect program. Omada w...
Omada Health Reports First Quarter 2026 Results
Revenue up 42% Year over Year ; Total Members Surpass One Million; Expanded Channels Now Include All Three of the Nation's Leading PBMs SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health, I...
Omada Health Proxy statement: Proxy filing
Omada Health filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Omada Health Proxy statement: Proxy filing
Omada Health filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Omada Health announces new study results on Omada members
Omada Health (OMDA) announced new study results demonstrating that Omada members in its GLP-1 Care Track lost, on average, 1.8 times more total weight and reduced their body fat percentage…
Omada Health Helps Members on GLP‑1s Lose More Fat, Preserve Muscle Mass, and Improve Mental Health, New Study Finds
SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first provider of between-visit care, announced new study results demonstrating that Omada members in its GLP...
Omada Health to Announce First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its first quarter 2026 results on Thu...
Omada Health initiated with an Outperform at Citizens
Citizens initiated coverage of Omada Health (OMDA) with an Outperform rating and $18 price target Omada is a leading, next-generation virtual care provider, the analyst tells investors in a research…
Omada Health price target lowered to $15 from $20 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson lowered the firm’s price target on Omada Health (OMDA) to $15 from $20 and keeps an Outperform rating on the shares. The firm made several…
Omada Health price target lowered to $26 from $32 at JPMorgan
JPMorgan lowered the firm’s price target on Omada Health (OMDA) to $26 from $32 and keeps an Overweight rating on the shares. The firm updated the company’s estimates. Published first…
Omada Health price target lowered to $20 from $25 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson lowered the firm’s price target on Omada Health (OMDA) to $20 from $25 and keeps an Outperform rating on the shares.
Omada Health price target lowered to $18 from $27 at BMO Capital
BMO Capital analyst Sean Dodge lowered the firm’s price target on Omada Health (OMDA) to $18 from $27 but keeps an Outperform rating on the shares after it’s Q4 results…
Omada Health price target lowered to $30 from $32 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Omada Health (OMDA) to $30 from $32 and keeps an Overweight rating on the shares. A “key debate” is how conservative is…